Tempo Wealth LLC Makes New $627,000 Investment in AbbVie Inc. $ABBV

Tempo Wealth LLC acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,745 shares of the company’s stock, valued at approximately $627,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. KW Wealth Management LLC lifted its position in AbbVie by 10.0% during the fourth quarter. KW Wealth Management LLC now owns 4,573 shares of the company’s stock worth $1,045,000 after buying an additional 415 shares during the period. MidFirst Bank acquired a new position in shares of AbbVie during the 4th quarter valued at about $9,238,000. Astoria Portfolio Advisors LLC. increased its stake in shares of AbbVie by 60.4% during the 4th quarter. Astoria Portfolio Advisors LLC. now owns 5,092 shares of the company’s stock valued at $1,168,000 after acquiring an additional 1,918 shares during the last quarter. Barnes Wealth Management Group Inc lifted its holdings in shares of AbbVie by 5.3% during the 4th quarter. Barnes Wealth Management Group Inc now owns 1,337 shares of the company’s stock worth $305,000 after acquiring an additional 67 shares during the period. Finally, SG Trading Solutions LLC purchased a new position in shares of AbbVie during the 4th quarter worth about $3,239,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

AbbVie Stock Performance

NYSE ABBV opened at $216.63 on Friday. The firm has a market capitalization of $382.74 billion, a price-to-earnings ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. AbbVie Inc. has a one year low of $181.73 and a one year high of $244.81. The company’s 50 day moving average price is $212.18 and its 200 day moving average price is $218.76.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the previous year, the firm earned $2.46 earnings per share. AbbVie’s revenue for the quarter was up 12.4% on a year-over-year basis. Sell-side analysts forecast that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 340.89%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a report on Thursday, April 30th. William Blair reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a report on Monday, June 8th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.